Abstract
Pulmonary embolism is a common medical problem and although many patients have a benign clinical course there is still appreciable morbidity and mortality associated with the diagnosis. It is generally accepted that thrombolysis is the treatment of choice in patients with haemodynamic compromise but the management of haemodynamically stable patients with large pulmonary embolism is less well defined. A significant proportion of this latter group have a complicated hospital course and require escalation of therapy. There is increasing interest in markers that can potentially identify at risk patients who would benefit from intensive monitoring and therapy. Conversely these markers would also identify low risk patients who could be managed on an outpatient basis alone. This article reviews the current evidence for the use of the clinical history and examination, electrocardiogram, echocardiography, computed tomography and cardiac biochemical markers, principally troponin and brain natriuretic peptide, for risk stratification in pulmonary embolism.
Keywords: Pulmonary embolism, risk, stratification, BNP, pro-BNP, CT, troponin, echocardiogram, electrocardiogram
Current Respiratory Medicine Reviews
Title: Risk Stratification in Pulmonary Embolism
Volume: 1 Issue: 3
Author(s): Mark Weatherhead and George Antunes
Affiliation:
Keywords: Pulmonary embolism, risk, stratification, BNP, pro-BNP, CT, troponin, echocardiogram, electrocardiogram
Abstract: Pulmonary embolism is a common medical problem and although many patients have a benign clinical course there is still appreciable morbidity and mortality associated with the diagnosis. It is generally accepted that thrombolysis is the treatment of choice in patients with haemodynamic compromise but the management of haemodynamically stable patients with large pulmonary embolism is less well defined. A significant proportion of this latter group have a complicated hospital course and require escalation of therapy. There is increasing interest in markers that can potentially identify at risk patients who would benefit from intensive monitoring and therapy. Conversely these markers would also identify low risk patients who could be managed on an outpatient basis alone. This article reviews the current evidence for the use of the clinical history and examination, electrocardiogram, echocardiography, computed tomography and cardiac biochemical markers, principally troponin and brain natriuretic peptide, for risk stratification in pulmonary embolism.
Export Options
About this article
Cite this article as:
Weatherhead Mark and Antunes George, Risk Stratification in Pulmonary Embolism, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774598027
DOI https://dx.doi.org/10.2174/157339805774598027 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Cellular Senescence During Vascular Calcification: A Key Paradigm in Aging Research
Current Aging Science Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Retinoid-Induced Limb Malformations
Current Pharmaceutical Design Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Experimental Antioxidant Biotherapy for Protection of the Vascular Wall by Modified Forms of Superoxide Dismutase and Catalase
Current Pharmaceutical Design Intimal Hyperplasia in Murine Models
Current Drug Targets Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets Contraception in Women with Medical Conditions
Current Women`s Health Reviews Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Toll-like Receptor as a Molecular Link between Metabolic Syndrome and Inflammation: A Review
Current Drug Targets Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Vasoprotective Actions of the Atrial Natriuretic Peptide
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi: A Sulfated Glycoprotein Antigen as Relevant Candidate for Vaccine Development and Drug Target. A Review
Current Medicinal Chemistry Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report
Current Stem Cell Research & Therapy Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design